Eli Lilly just secured a significant regulatory win. The FDA approval of Inluriyo and Verzenio from Eli Lilly, announced September 18, 2026, clears an all-oral combination therapy for a specific, harder-to-treat form of advanced breast cancer — and the clinical trial data behind it is drawing real attention in the oncology world.
If you or a loved one has ER-positive, HER2-negative breast cancer with an ESR1 mutation, or you’re simply trying to understand what this approval actually changes, here’s a clear, current breakdown of what happened and why it matters.
What Did the FDA Approve?
The U.S. Food and Drug Administration granted full approval to Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib), for adults with:
- Estrogen receptor-positive (ER+) breast cancer
- HER2-negative (HER2−) breast cancer
- An ESR1 mutation, as detected by an FDA-authorized test
- Locally advanced or metastatic disease
- Disease that has progressed following at least one prior line of endocrine therapy
This is a label expansion, not a brand-new drug approval. Inluriyo already had FDA approval as a standalone treatment (monotherapy) for the same patient population, first granted in September 2025. This new approval specifically clears it for use alongside Verzenio, Lilly’s existing CDK4/6 inhibitor, rather than on its own.
How the Two Drugs Work Together
Understanding why this combination matters requires a quick look at what each drug actually does:
- Inluriyo (imlunestrant) is a once-daily oral estrogen receptor antagonist. It works by blocking and breaking down estrogen receptors that can fuel the growth of certain breast cancers.
- Verzenio (abemaciclib) is a twice-daily oral CDK4/6 inhibitor, a class of drug that slows cancer cell division.
Together, Lilly describes the combination as targeting “the two central drivers” of ER-positive breast cancer simultaneously — cutting off the hormone signal driving tumor growth while also directly slowing the rate at which cancer cells divide.
The Clinical Trial Data Behind the Approval
The approval is based on results from the Phase 3 EMBER-3 trial, which evaluated the combination in patients with previously treated, ESR1-mutated metastatic breast cancer.
Here’s what the trial found:
- Patients who received Inluriyo plus Verzenio achieved a median progression-free survival (PFS) of 11.1 months.
- Patients who received Inluriyo alone had a median PFS of 5.5 months.
- The combination represented a 47% reduction in the risk of disease progression or death compared to Inluriyo monotherapy.
- The trial specifically evaluated the benefit of switching to the combination at the point of clinical progression on prior therapy, rather than starting it earlier in treatment.
Jake Van Naarden, president of Lilly Oncology, told Fierce Pharma that given the meaningfully longer progression-free survival, he expects most eligible patients to choose the combination over Inluriyo alone going forward.
Known Side Effects and Risks
As with any oncology treatment, this combination carries real risks that patients and doctors will need to weigh. According to Lilly’s own disclosures, potential side effects include:
- Severe diarrhea
- Decreased neutrophil counts — notably common, occurring in 86% of patients in the combination arm, with Grade 3 or 4 decreases in 21%
- Decreased hemoglobin, lymphocytes, and platelets
- Nausea and fatigue
- Interstitial lung disease (ILD) / pneumonitis — a known risk specifically associated with Verzenio and other CDK4/6 inhibitors, which can be severe or life-threatening in rare cases
- Liver problems and blood clots
Lilly noted that most adverse events observed in the trial were Grade 1–2 in severity, and treatment discontinuation was relatively uncommon — permanent discontinuation occurred in just 1% of patients for Inluriyo and 3.4% for Verzenio within the combination arm.
How This Fits Into a Competitive Market
This approval lands amid active competition in what’s known as the oral SERD (selective estrogen receptor degrader) space, where multiple pharmaceutical companies are racing to establish their treatments as the preferred option for ESR1-mutated breast cancer.
AstraZeneca has its own competing regimen, and data from its Phase 3 SERENA-6 trial showed a median PFS of 16 months for first-line patients using its combination, compared to 9.2 months for those who stayed on existing therapy. It’s worth noting these results come from separate trials with different patient populations — SERENA-6 evaluated switching earlier, before disease progression, while EMBER-3 specifically tested switching at the point of progression. Lilly has argued that waiting until clinical progression before switching treatments can help maximize the total time a patient’s disease stays under control, rather than switching preemptively.
Inluriyo’s Broader Development Pipeline
This marks Inluriyo’s second FDA approval in less than a year, following its initial approval as a monotherapy in September 2025. Lilly isn’t stopping here — the drug is also being studied in the Phase 3 EMBER-4 trial, evaluating its use in an earlier, adjuvant setting for people with ER+, HER2− early-stage breast cancer who face an increased risk of recurrence after standard endocrine therapy.
If that trial succeeds, it could eventually expand Inluriyo’s use to a much larger population of breast cancer patients, beyond those with advanced or metastatic disease.
What This Means for Patients
For patients with this specific genetic and hormonal profile, this approval offers a new, well-supported treatment option. A few practical points worth understanding:
- This combination is specifically for patients whose cancer has an ESR1 mutation, identified through an FDA-authorized diagnostic test — not all ER+/HER2− breast cancers qualify.
- It’s intended for patients whose disease has already progressed on at least one prior endocrine therapy, positioning it as a later-line treatment option rather than a first-line one.
- Both medications are taken orally, which may offer a more convenient treatment experience compared to infusion-based therapies for eligible patients.
- As with any new treatment decision, this is something to discuss directly with an oncologist, who can evaluate individual test results, treatment history, and overall health to determine whether this combination is appropriate.
Frequently Asked Questions
1. What did the FDA approve for Eli Lilly’s Inluriyo and Verzenio? The FDA granted full approval for Inluriyo used in combination with Verzenio to treat adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one prior endocrine therapy.
2. How well did the combination perform in clinical trials? In the Phase 3 EMBER-3 trial, the combination achieved a median progression-free survival of 11.1 months, compared to 5.5 months for Inluriyo alone — a 47% reduction in the risk of disease progression or death.
3. Is this a new drug, or an expanded approval for existing drugs? It’s a label expansion. Inluriyo was already FDA-approved as a standalone treatment since September 2025; this approval adds its use in combination with Verzenio.
4. What are the main side effects of this combination? Common side effects include decreased neutrophil counts, diarrhea, decreased hemoglobin and platelets, nausea, and fatigue, along with more serious risks like interstitial lung disease, liver problems, and blood clots.
5. Who is eligible for this treatment? Adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, identified through an FDA-authorized test, whose disease has progressed on at least one prior line of endocrine therapy.
6. How does this compare to other breast cancer treatments in development? It competes in the oral SERD treatment category, where AstraZeneca has its own combination showing strong results in a different trial setting, though the two treatments haven’t been directly compared head-to-head.
7. Could this treatment eventually be used earlier in breast cancer treatment? Possibly. Lilly is studying Inluriyo in the Phase 3 EMBER-4 trial for use in earlier-stage, adjuvant treatment settings, which could expand its approved use if successful.
Final Thoughts
The FDA approval of Inluriyo and Verzenio from Eli Lilly gives patients with ESR1-mutated, ER+/HER2− advanced breast cancer a new all-oral treatment option backed by a meaningful improvement in progression-free survival compared to monotherapy alone. As with any cancer treatment decision, eligibility and appropriateness depend on individual test results and treatment history, making a conversation with an oncologist the essential next step for anyone considering this option.
Given Lilly’s active pipeline for this drug, it’s also worth watching for further developments as the EMBER-4 trial progresses in earlier-stage breast cancer settings.
This article covers a pharmaceutical regulatory approval for informational purposes and is not medical advice. Please consult an oncologist or healthcare provider regarding any specific treatment decision.